肺炎球菌结合疫苗的分数剂量——一项非劣效性试验
该研究在肯尼亚健康婴儿中随机分组,比较10价和13价肺炎球菌结合疫苗(PCV10和PCV13)分数剂量与全剂量的免疫原性及疫苗血清型携带率。结果显示,40%剂量PCV13在基础系列后13种血清型中12种、加强后13种均达非劣效;20%剂量PCV13及40%、20%剂量PCV10未达非劣效。
要点
- 40%剂量PCV13在基础系列后12/13种血清型、加强后13/13种血清型达非劣效。
- 20%剂量PCV13及40%、20%剂量PCV10未达非劣效标准。
- 9月龄和18月龄时PCV13各组疫苗血清型携带率相似。
核心结论
- 在三剂次方案(两剂基础加一剂加强)中,40%剂量PCV13对所有纳入血清型非劣效于全剂量。
- 更低剂量的PCV13和PCV10未达到非劣效性标准。
研究设计与样本
- 在肯尼亚将健康婴儿随机分配至七个等样本量试验组。
- A至F组分别接受PCV13全剂量、40%剂量、20%剂量或PCV10全剂量、40%剂量、20%剂量,均为基础两剂加加强一剂。
- G组接受PCV10全剂量三剂基础免疫,无加强剂。
- 免疫原性在基础系列后4周和加强剂后4周评估。
- 携带率在9月龄和18月龄评估。
主要发现
- 符合方案分析中,40%剂量PCV13在基础系列后13种血清型中12种、加强后13种均达非劣效。
- 20%剂量PCV13及40%和20%剂量PCV10的免疫原性未非劣效于全剂量。
- PCV13各组在9月龄和18月龄时疫苗血清型携带率相似。
关键数值与推荐
- 基础系列后4周,阈值应答参与者百分比差异不超过10%可宣布非劣效。
- 加强后4周,IgG几何平均浓度(GMC)比值大于0.5可宣布非劣效。
- PCV10组至少8/10种疫苗型、PCV13组至少10/13种疫苗型满足非劣效标准,该剂量预设为非劣效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal conjugate vaccines are an expensive component of the routine immunization schedule. Fractional-dose regimens may be one option to increase the sustainability of the vaccine program. METHODS: We assessed whether the immunogenicity of fractional doses of the 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10 [GSK] and PCV13 [Pfizer], respectively) would be noninferior to that of the full doses and analyzed the prevalence of vaccine-serotype carriage. We randomly assigned healthy infants in Kenya to one of seven equal-sized trial groups. Participants in groups A through F were assigned to receive either a fractional or full dose of PCV10 or PCV13, administered as two primary doses plus one booster dose. In group A, participants received a full dose of PCV13; group B, a 40% dose of PCV13; group C, a 20% dose of PCV13; group D, a full dose of PCV10; group E, a 40% dose of PCV10; and group F, a 20% dose of PCV10. Participants in the seventh group (group G) received a full dose of PCV10 as three primary doses without a booster. Immunogenicity was assessed 4 weeks after the primary series of doses and 4 weeks after the booster dose. Noninferiority could be declared 4 weeks after the primary series if the difference in the percentage of participants with a threshold response was not more than 10% and 4 weeks after administration of the booster if the ratio of the geometric mean concentration (GMC) of IgG was more than 0.5. A vaccine dose was prespecified as noninferior if it met the noninferiority criterion for at least 8 of the 10 vaccine types in the PCV10 groups or at least 10 of the 13 vaccine types in the PCV13 groups. Carriage was assessed when participants were 9 months and 18 months of age. RESULTS: In the per-protocol analysis, 40% of a full dose of PCV13 met the noninferiority criterion for 12 of 13 serotypes after the primary series and for 13 of 13 serotypes after the booster. The immunogenicity of the 20% dose of PCV13 and of the 40% and 20% doses of PCV10 was not noninferior to that of the full doses. The prevalence of vaccine-serotype carriage was similar across the PCV13 groups at 9 months and 18 months of age. CONCLUSIONS: In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT03489018; Pan African Clinical Trial Registry number, PACTR202104717648755.).
引用
- Gallagher KE, Lucinde R, Bottomley C, et al. Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial. N Engl J Med. 2024. PMID: 39330966. doi:10.1056/NEJMoa2314620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。